Vanda Pharmaceuticals Inc. (VNDA) Financial Statements (2026 and earlier)

Company Profile

Business Address 2200 PENNSYLVANIA AVE NW
WASHINGTON, DC 20037
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments84,851102,316135,821135,029432,813367,740
Cash and cash equivalent84,851102,316135,821135,02952,07161,031
Short-term investments     380,742306,709
Restricted cash and investments103     
Receivables54,57847,10134,15533,51232,46730,036
Inventory, net of allowances, customer advances and progress billings1,8521,7261,3571,1941,0251,280
Inventory1,8521,7261,3571,1941,0251,280
Debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss✕✕✕252,520333,368 ✕
Other undisclosed current assets205,878287,7479,09316,18911,99610,089
Total current assets:347,262438,890432,946519,292478,301409,145
Noncurrent Assets
Inventory, Noncurrent9,1687,7878,84810,2967,2275,091
Finance lease, right-of-use asset, after accumulated amortization7,3434,943    
Operating lease, right-of-use asset3,9235,6027,1038,4009,27210,459
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization2,2482,1322,0372,5733,1134,136
Intangible asset, including goodwill, after accumulated amortization117,089114,096121,36918,56520,08121,559
Intangible asset, excluding goodwill, after accumulated amortization117,089114,096121,36918,56520,08121,559
Restricted cash and investments366     
Deferred income tax assets  81,44075,00074,03974,87881,516
Other undisclosed noncurrent assets1,5491,3141,1371,0829201,550
Total noncurrent assets:141,686217,314215,494114,955115,491124,311
TOTAL ASSETS:488,948656,204648,440634,247593,792533,456
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:68,29739,08638,46045,55134,43831,509
Employee-related liabilities✕✕✕✕6,8396,51510,951
Accrued liabilities28,88519,35613,22614,22014,60511,918
Other undisclosed accounts payable and accrued liabilities39,41219,73025,23424,49213,3188,640
Other undisclosed current liabilities76,86560,89549,23745,88539,98134,427
Total current liabilities:145,16299,98187,69791,43674,41965,936
Noncurrent Liabilities
Long-term debt and lease obligation4,0763,146  10,05511,497
Finance lease, liability4,0763,146    
Liabilities, other than long-term debt12,52414,53115,83315,6134,3902,757
Other liabilities9,5339,5878,8276,8004,3902,757
Operating lease, liability2,9914,9447,0068,81310,05511,497
Total noncurrent liabilities:16,60017,67715,83315,61314,44514,254
Total liabilities:161,762117,658103,530107,04988,86480,190
Equity
Equity, attributable to parent327,186538,546544,910527,198504,928453,266
Common stock595858575655
Additional paid in capital721,264712,706700,274686,235669,223650,300
Accumulated other comprehensive income (loss)62974(30)(1,193)(175)239
Accumulated deficit(394,766)(174,292)(155,392)(157,901)(164,176)(197,328)
Total equity:327,186538,546544,910527,198504,928453,266
TOTAL LIABILITIES AND EQUITY:488,948656,204648,440634,247593,792533,456

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues216,105198,772192,640254,382268,682248,168
Cost of revenue
(Cost of Product and Service Sold)		(13,044)(11,314)(14,796)(24,282)(25,629)(23,364)
Gross profit:203,061187,458177,844230,100243,053224,804
Operating expenses(354,229)(228,118)(191,796)(223,771)(200,888)(197,565)
Operating income (loss):(151,168)(40,660)(13,952)6,32942,16527,239
Interest and debt expense (343)(32)    
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes     4,416
Income (loss) from continuing operations before equity method investments, income taxes:(151,511)(40,692)(13,952)6,32942,16531,655
Other undisclosed income from continuing operations before income taxes12,86417,77120,2914,971199 
Income (loss) from continuing operations before income taxes:(138,647)(22,921)6,33911,30042,36431,655
Income tax expense (benefit)(81,827)4,021(3,830)(5,025)(9,212)(8,318)
Income (loss) from continuing operations:(220,474)(18,900)2,5096,27533,15223,337
Income before gain (loss) on sale of properties:✕✕✕✕✕33,15223,337
Net income (loss) available to common stockholders, diluted:(220,474)(18,900)2,5096,27533,15223,337

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net income (loss):(220,474)(18,900)2,5096,27533,15223,337
Other comprehensive income (loss)5551041,163(1,018)(414)(10)
Comprehensive income (loss):(219,919)(18,796)3,6725,25732,73823,327
Other undisclosed comprehensive income, net of tax, attributable to parent      
Comprehensive income (loss), net of tax, attributable to parent:(219,919)(18,796)3,6725,25732,73823,327

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios